Finance

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/news/news_headline_open_108x81._800x533_L_1419519630.jpg https://www.investing.com/news/world-news/photos-likely-show-undeclared-north-korea-uranium-enrichment-site-analysts-say-3616525 Reuters

leading-8"> SHANGHAI/BEIJING (Reuters) - Shanghai halted transportation links, recalled ships and shut tourism spots including Shanghai Disney Resort on Sunday as it...

Suns season tickets,” he said. “I used to go to games all the time for that, but then I moved. I live...

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/press-releases/macrogenics-announces-updated-efficacy--safety-data-from-tamarack-phase-2-study-of-vobra-duo-in-mcrpc-patients-at-esmo-congress-2024-93CH-3616520 Investing.com

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/press-releases/23andme-therapeutics-announces-phase-2-results-for-two-additional-cancer-cohorts-and-correlative-biomarker-data-from-23me00610-study-93CH-3616521 Investing.com

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/press-releases/akeso-published-firstever-efficacy-data-for-pd1vegf-bispecific-antibody-ivonescimab-with-or-without-cd47-antibody-plus-folfoxiri-for-mcrc-at-esmo-2024-93CH-3616522 Investing.com

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/press-releases/akeso-published-ivonescimab-plus-ligufalimab-as-firstline-treatment-for-pdl1positive-recurrentmetastatic-head-and-neck-squamous-cell-carcinoma-at-esmo-2024-93CH-3616523 Investing.com

Investing.com